Literature DB >> 36127465

How location and cellular signaling combine to activate the NLRP3 inflammasome.

Anil Akbal1, Alesja Dernst1, Marta Lovotti1, Matthew S J Mangan1, Róisín M McManus1,2, Eicke Latz3,4,5,6.   

Abstract

NOD-, LRR-, and pyrin domain-containing 3 (NLRP3) is a cytosolic innate immune sensor of cellular stress signals, triggered by infection and sterile inflammation. Upon detection of an activating stimulus, NLRP3 transitions from an inactive homo-oligomeric multimer into an active multimeric inflammasome, which promotes the helical oligomeric assembly of the adaptor molecule ASC. ASC oligomers provide a platform for caspase-1 activation, leading to the proteolytic cleavage and activation of proinflammatory cytokines in the IL-1 family and gasdermin D, which can induce a lytic form of cell death. Recent studies investigating both the cellular requirement for NLRP3 activation and the structure of NLRP3 have revealed the complex regulation of NLRP3 and the multiple steps involved in its activation. This review presents a perspective on the biochemical and cellular processes controlling the assembly of the NLRP3 inflammasome with particular emphasis on structural regulation and the role of organelles. We also highlight the latest research on metabolic control of this inflammatory pathway and discuss promising clinical targets for intervention.
© 2022. The Author(s).

Entities:  

Keywords:  Inflammasome; Localization; Mechanism; NLRP3; Regulation; Structure

Year:  2022        PMID: 36127465     DOI: 10.1038/s41423-022-00922-w

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   22.096


  153 in total

Review 1.  The inflammasome.

Authors:  Virginie Petrilli; Stéphanie Papin; Jürg Tschopp
Journal:  Curr Biol       Date:  2005-08-09       Impact factor: 10.834

Review 2.  Strategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space.

Authors:  Adam G Schwaid; Kerrie B Spencer
Journal:  J Med Chem       Date:  2020-12-22       Impact factor: 7.446

Review 3.  Homeostasis-altering molecular processes as mechanisms of inflammasome activation.

Authors:  Adrian Liston; Seth L Masters
Journal:  Nat Rev Immunol       Date:  2017-02-06       Impact factor: 53.106

Review 4.  Inflammasome Complexes: Emerging Mechanisms and Effector Functions.

Authors:  Vijay A K Rathinam; Katherine A Fitzgerald
Journal:  Cell       Date:  2016-05-05       Impact factor: 41.582

Review 5.  Targeting the NLRP3 inflammasome in inflammatory diseases.

Authors:  Matthew S J Mangan; Edward J Olhava; William R Roush; H Martin Seidel; Gary D Glick; Eicke Latz
Journal:  Nat Rev Drug Discov       Date:  2018-07-20       Impact factor: 84.694

6.  Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity.

Authors:  D Perregaux; C A Gabel
Journal:  J Biol Chem       Date:  1994-05-27       Impact factor: 5.157

7.  Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression.

Authors:  Franz G Bauernfeind; Gabor Horvath; Andrea Stutz; Emad S Alnemri; Kelly MacDonald; David Speert; Teresa Fernandes-Alnemri; Jianghong Wu; Brian G Monks; Katherine A Fitzgerald; Veit Hornung; Eicke Latz
Journal:  J Immunol       Date:  2009-07-01       Impact factor: 5.422

Review 8.  The NLRP3 inflammasome: molecular activation and regulation to therapeutics.

Authors:  Karen V Swanson; Meng Deng; Jenny P-Y Ting
Journal:  Nat Rev Immunol       Date:  2019-08       Impact factor: 53.106

9.  Inflammasome signaling and regulation of interleukin-1 family cytokines.

Authors:  Amy H Chan; Kate Schroder
Journal:  J Exp Med       Date:  2020-01-06       Impact factor: 14.307

Review 10.  The NLRP3-inflammasome as a sensor of organelle dysfunction.

Authors:  Paula I Seoane; Bali Lee; Christopher Hoyle; Shi Yu; Gloria Lopez-Castejon; Martin Lowe; David Brough
Journal:  J Cell Biol       Date:  2020-12-07       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.